Double Blind, Randomized, Placebo-Controlled, Phase 2A Mechanistic Study to Evaluate the Effect of ISIS 449884 (ISIS-GCGRRx) on Hepatic Lipid and Glycogen Content in Patients With Type 2 Diabetes Being Treated With Metformin
Active, no longer recruiting
Phase of Trial: Phase II
Latest Information Update: 21 Aug 2017
At a glance
- Drugs IONIS-GCGRRx (Primary)
- Indications Type 2 diabetes mellitus
- Focus Adverse reactions; Pharmacodynamics; Therapeutic Use
- Sponsors Ionis Pharmaceuticals
- 21 Aug 2017 The trial has been completed in Slovakia (End date: 2017-05-22).
- 09 Aug 2017 The trial has been completed in Hungary (End date: 2017-05-22) according to European Clinical Trials Database record.
- 02 Aug 2017 The trial has been completed in Austria (End date: 19-04-2017).